Calcium-D3 Nikomed Forte Chewable Tablets, No. 60 per bottle

Made to order
$54.00

Composition

Active ingredient: Each tablet contains 1,250 mg of calcium carbonate, which is equivalent to 500 mg of calcium, and cholecalciferol (vitamin D3)—10 mcg (400 IU) in the form of 4 mg of cholecalciferol concentrate*;

Excipients: xylitol (E 967), lemon-flavored granules (isomalt (E 953), lemon flavoring, mono- and diglycerides of fatty acids), povidone, magnesium stearate, sucralose

*Composition of cholecalciferol concentrate: cholecalciferol, DL-α-tocopherol, medium-chain triglycerides, modified corn starch, sucrose, sodium ascorbate, colloidal anhydrous silicon dioxide.

Dosage form

Chewable tablets.

Main physical and chemical properties: round, white, biconvex, uncoated tablets; the presence of specks and slight irregularities along the edges is permitted. A small amount of powder may be present at the bottom of the bottle.

Pharmacotherapeutic group

Mineral supplements. Calcium, combinations with vitamin D and/or other medicinal products.

ATX code A12A X.

Pharmacological Properties

Pharmacodynamics.

Vitamin D3 increases calcium absorption in the intestine.

The intake of calcium and vitamin D3 prevents an increase in parathyroid hormone (PTH) levels, which is caused by calcium deficiency and leads to increased bone resorption (the leaching of calcium from the bones).

A clinical study in hospitalized patients with vitamin D deficiency showed that daily intake of 2 tablets of 500 mg calcium and 400 IU vitamin D for 6 months normalized levels of the 25-hydroxylated metabolite of vitamin D3 and reduced the symptoms of secondary hyperparathyroidism and alkaline phosphatase levels.

Pharmacokinetics.

Calcium.

Absorption. Typically, approximately 30% of the administered dose of calcium is absorbed through the gastrointestinal tract.

Distribution and Biotransformation. 99% of calcium is concentrated in the body’s hard tissues (bones, teeth); 1% of calcium is found in the intracellular and extracellular compartments. Approximately 50% of calcium in the blood is in the physiologically active ionized form, nearly 10% is bound to citrates, phosphates, and other anions, and the remaining 40% is bound to proteins, primarily albumin.

Elimination. Calcium is excreted in feces, urine, and sweat. Renal excretion depends on the rate of glomerular filtration and tubular reabsorption of calcium.

Cholecalciferol.

Absorption. Vitamin D3 is readily absorbed in the small intestine.

Distribution and Biotransformation. Cholecalciferol and its metabolites circulate in the blood in a bound state to a specific globulin. In the liver, cholecalciferol is converted by hydroxylation to 25-hydroxycolecalciferol. It is then converted into the active form, 1,25-dihydroxycholecalciferol, in the kidneys. 1,25-dihydroxycholecalciferol is the metabolite responsible for increased calcium absorption. Vitamin D3 that has not been metabolized is stored in adipose and muscle tissues.

Excretion. Vitamin D3 is excreted in feces and urine.

Indications

Prevention and treatment of calcium and vitamin D deficiency in adult patients at risk.

Supplemental use of vitamin D and calcium as an adjunct to specific osteoporosis therapy in patients at risk of developing calcium and vitamin D deficiency.

Contraindications

  • Hypersensitivity to the active ingredient or to any other components of the drug;
  • severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73 m²);
  • diseases and/or conditions associated with hypercalcemia and/or hypercalciuria;
  • urolithiasis (kidney stones);
  • hypervitaminosis D.

Drug Interactions and Other Interactions

Thiazide diuretics reduce urinary calcium excretion. During concomitant therapy, serum calcium levels should be monitored, as the risk of hypercalcemia is increased.

Calcium carbonate may interfere with the absorption of tetracycline-class drugs; therefore, these drugs should be taken at least 2 hours before or 4–6 hours after taking Calcium-D3 Nicomed Forte.

Hypercalcemia may potentiate the toxicity of cardiac glycosides due to calcium and vitamin D. Cardiac function should be monitored via ECG, serum calcium levels, and clinical status.

To prevent a decrease in the absorption of bisphosphonates, it is recommended to take Calcium-D3 Nicomed Forte no earlier than 1 hour after taking them.

When taken concurrently with calcium, the effectiveness of levothyroxine may be reduced due to decreased absorption. Levothyroxine should be taken at least 4 hours after taking Calcium-D3 Nicomed Forte.

Concomitant use of calcium may affect the absorption of quinolone antibiotics. Quinolone antibiotics should be taken 2 hours before or 6 hours after taking Calcium-D3 Nicomed Forte.

Calcium salts may reduce the absorption of ranelate iron, zinc, and strontium. Therefore, ranelate iron, zinc, and strontium preparations should be taken at least 2 hours before or after taking Calcium-D3 Nicomed Forte.

Treatment with orlistat may potentially interfere with the absorption of fat-soluble vitamins (e.g., vitamin D3).

Special Considerations

During long-term treatment with this medication, serum calcium and creatinine levels, as well as renal function, should be monitored, especially in elderly patients receiving concomitant therapy with cardiac glycosides or diuretics (see the section “Interactions with Other Medications and Other Forms of Interaction”) and in patients with a high tendency to develop dental calculus. If signs of hypercalcemia or renal insufficiency appear, the dose should be reduced or the drug discontinued.

This medication should be used with caution in patients with hypercalcemia or signs of renal insufficiency, and calcium and phosphate levels should be monitored. Be aware of the potential risk of soft-tissue calcification. In patients with severe renal insufficiency, vitamin D in the form of cholecalciferol cannot be metabolized normally; therefore, other forms of vitamin D should be used. In such patients, serum calcium levels and renal function should be monitored regularly.

Calcium-D3 Nicomed Forte should be used with caution in patients with sarcoidosis due to the risk of increased metabolism of vitamin D3 into its active form. Serum and urinary calcium levels should be monitored.

Calcium-D3 Nicomed Forte should be used with caution in immobilized patients with osteoporosis due to the risk of developing hypercalcemia.

To avoid overdose, the intake of calcium and vitamin D3 from other sources must be taken into account within the recommended daily intake limits for calcium and vitamin D3.

Patients with rare hereditary fructose intolerance, sucrase-isomaltase deficiency, or glucose-galactose malabsorption should not take this medication, as it contains isomalt and sucrose.

Pregnancy and Lactation

Pregnancy. Calcium-D3 Nicomed Forte may be used during pregnancy in cases of calcium and vitamin D deficiency. The daily dose should not exceed 2,500 mg of calcium and 4,000 IU of vitamin D. Animal studies have shown that vitamin D in high doses is toxic to reproduction. Pregnant women should avoid overdosing on this medication, as prolonged hypercalcemia has an adverse effect on the fetus. There is no evidence that vitamin D, when taken in recommended doses, can cause teratogenic effects in humans.

Breastfeeding. Calcium-D3 Nicomed Forte may be used during breastfeeding. Calcium, vitamin D3, and its metabolites may pass into breast milk; therefore, the infant’s intake of calcium and vitamin D3 from other sources must be taken into account.

Effects on the Ability to Drive and Operate Machinery

There are no known data on the effect of Calcium-D3 Nicomed Forte on reaction time while driving or operating other machinery.

Directions for Use and Dosage

This medication is intended for oral use. The tablet should be chewed or dissolved.

Adults and elderly patients: 1 tablet twice daily.

No dose adjustment is required for patients with hepatic insufficiency.

Patients with severe renal insufficiency should not take this medication (see the “Contraindications” section).

Children: This medication is not intended for use in children.

Overdose

Symptoms. An overdose of this medication may lead to vitamin D toxicity and hypercalcemia. Symptoms of hypercalcemia include: loss of appetite, thirst, nausea, vomiting, constipation, abdominal pain, muscle weakness, rapid fatigue, mental disorders, polydipsia, polyuria, bone pain, nephrocalcinosis, kidney stones, and cardiac arrhythmias in severe cases. Severe hypercalcemia can lead to coma and death. Persistently high calcium levels in the body can lead to irreversible kidney damage and soft tissue calcification.

Patients who consume large amounts of calcium and absorbable alkalis may experience milk-alkali syndrome; such patients require hospitalization.

Treatment: Symptomatic and supportive therapy. Discontinue the drug. Treatment with thiazide diuretics and cardiac glycosides should also be discontinued (see the “Interactions with Other Medications and Other Forms of Interaction” section). Gastric lavage should be performed in patients with impaired consciousness. It is necessary to administer large amounts of fluid and follow a diet with limited calcium intake. Depending on the severity of the overdose, loop diuretics, bisphosphonates, calcitonin, or corticosteroids—either alone or in combination—may be required. Serum electrolytes, renal function, and urine output should be monitored. In severe cases, the electrocardiogram (ECG) and central venous pressure (CVP) should be monitored.

Side Effects

Adverse effects are classified by frequency of occurrence as follows:

rare (≥ 1/1,000, < 1/100), very rare (≥ 1/10,000, < 1/1,000), very rare (< 1/10,000), unknown (frequency cannot be estimated from the available data).

Immune system disorders.

Unknown: hypersensitivity reactions, including angioedema and laryngeal edema.

Metabolic disorders.

Uncommon: hypercalcemia, hypercalciuria.

Very rare: milk-alkali syndrome (frequent urge to urinate, persistent headache, persistent loss of appetite, nausea or vomiting, atypical fatigue or weakness, hypercalcemia, alkalosis, renal failure) observed only in cases of overdose (see the “Overdose” section).

Gastrointestinal disorders.

  • Constipation, dyspepsia, flatulence, nausea, abdominal pain, diarrhea.

Skin and subcutaneous tissue disorders.

Very rare: itching, rash, hives.

Special Patient Populations.

Patients with renal insufficiency: there may be a risk of developing hyperphosphatemia, nephrolithiasis, and nephrocalcinosis (see the “Special Instructions and Precautions for Use” section).

Shelf life

30 months.

Storage conditions

Store the vial tightly closed at a temperature not exceeding 30 °C. Keep out of reach of children!

Packaging

30, 60, or 120 tablets per bottle. 1 bottle per cardboard box.

Conditions of Sale

Available without a prescription